Get the Stockscreener App
1.21
0.00%
0.00
Pre-market:
1.24
0.03
+2.48%
Cognition Therapeutics Inc stock is traded at $1.21, with a volume of 856.74K.
It is up +0.00% in the last 24 hours and up +6.14% over the past month.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
See More
Previous Close:
$1.21
Open:
$1.26
24h Volume:
856.74K
Relative Volume:
0.72
Market Cap:
$108.29M
Revenue:
-
Net Income/Loss:
$-19.58M
P/E Ratio:
-4.6954
EPS:
-0.2577
Net Cash Flow:
$-20.25M
1W Performance:
+0.00%
1M Performance:
+6.14%
6M Performance:
-24.38%
1Y Performance:
+305.63%
1-Day Range:
$1.21
$1.295
1-Week Range:
$1.12
$1.295
52-Week Range:
$0.25
$3.83
Cognition Therapeutics Inc Stock (CGTX) Company Profile
Name
Cognition Therapeutics Inc
Sector
Industry
Phone
412-481-2210
Address
2500 WESTCHESTER AVE, PURCHASE
Compare CGTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
1.21 | 108.29M | 0 | -19.58M | -20.25M | -0.2577 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Upgrade | B. Riley Securities | Neutral → Buy |
| Jul-30-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-03-21 | Initiated | B. Riley Securities | Buy |
| Nov-03-21 | Initiated | Oppenheimer | Outperform |
Cognition Therapeutics Inc Stock (CGTX) Latest News
CGTX Q1 2026 Earnings: EPS Beat Exceeds Estimates; Cash Runway Supports Alzheimer’s ProgramsShare Repurchase Impact - newsline.com
Cognition Therapeutics (CGTX) Rises 5.26% as Shares Approach Key ResistanceBullish Pattern Stocks - newsline.com
Cognition Therapeutics (CGTX) Gets a Buy from H.C. Wainwright - The Globe and Mail
Cognition Therapeutics (CGTX) Slips 5% as Biotech Momentum FadesIndex Put Call - newsline.com
Cognition Therapeutics Advances Zervimesine Toward Phase 3 DLB Trial - TipRanks
Cognition Therapeutics advances zervimesine toward registrational DLB psychosis program; cash into Q2 2027 - TradingView
[8-K] COGNITION THERAPEUTICS INC Reports Material Event - Stock Titan
Cognition Therapeutics Reviews Phase 2 Results With FDA - asatunews.co.id
Cognition Therapeutics Meets FDA and Reduces First Quarter Net Loss - HarianBasis.co
Is Cognition Therapeutics, Inc. (CGTX) Moving Closer to a Registrational Trial in Dementia With Lewy Bodies? - Insider Monkey
Cognition Therapeutics, Inc. CEO Lisa Ricciardi to Present at June Financial Conferences on DLB Psychosis Registration Program - Quiver Quantitative
Cognition Therapeutics Participating in Upcoming Investor Conferences - The Manila Times
CGTX Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Progress for Alzheimer’s PipelineFull Year Guidance - newsline.com
Cognition Therapeutics Inc. (CGTX) Q1 2026 Earnings: Narrower‑than‑Expected Loss as Clinical Progress ContinuesPreliminary Results - newsline.com
Cognition Therapeutics (CGTX) Edges Lower as Stock Hovers Near Key SupportPrice Momentum Stocks - The Legal Advocate
CGTX Stock Chart | COGNITION THERAPEUTICS INC (NASDAQ:CGTX) - ChartMill
Cognition Therapeutics (CGTX) Holds Steady Near Key Support LevelRatio Spread Trade - newsline.com
CGTX News | COGNITION THERAPEUTICS INC (NASDAQ:CGTX) - ChartMill
CGTX Stock Price, Quote & Chart | COGNITION THERAPEUTICS INC (NASDAQ:CGTX) - ChartMill
Cognition Therapeutics (CGTX) Slides 1.59% as Biotech Sector Headwinds PersistSentiment Shift - The Legal Advocate
Cognition Therapeutics Inc. (CGTX) Slips Modestly as Stock Hovers Near Support ZoneBPI Bear Confirmed - The Legal Advocate
CGTX Q1 2026 Earnings: Narrower Loss Exceeds Estimates as Pre-Revenue Biotech Advances PipelineFree Cash Flow Trends - Newser
CGTX Q1 2026 Earnings: Cognition Therapeutics Reports Narrower-Than-Expected Loss, No Revenue YetShort-Term Outlook - The Legal Advocate
Cognition Therapeutics Inc. (CGTX) Q1 2026 Earnings: Narrower Loss on Lower Expenses, No Revenue ReportedGuidance Revision Trend - The Legal Advocate
Cognition Therapeutics Advances Zervimesine (CT1812) Toward Registrational Trial for Dementia with Lewy Bodies Psychosis After Positive FDA Meeting - Minichart
Cognition Therapeutics discusses FDA meeting on DLB drug trial By Investing.com - Investing.com South Africa
Cognition Therapeutics discusses FDA meeting on DLB drug trial - Investing.com
Cognition Therapeutics Advances Zervimesine Toward Late-Stage DLB Trial - TipRanks
Cognition Therapeutics, Inc. Reports Positive FDA Meeting on Zervimesine Development for Dementia with Lewy Bodies Psychosis - Quiver Quantitative
Cognition Therapeutics completes FDA meeting, sees path for registrational DLB psychosis program - TradingView
Cognition Therapeutics (CGTX) outlines FDA path for zervimesine DLB psychosis trial - Stock Titan
FDA, Cognition discuss next trial for Lewy body dementia psychosis drug - Stock Titan
Cognition Therapeutics Completes Meeting with FDA for - GlobeNewswire
Cognition Therapeutics, Inc.Common Stock (NQ: CGTX - The Chronicle-Journal
CGTX Should I Buy - Intellectia AI
TradingKey - TradingKey
Cognition Therapeutics receives donation to extend DLB program By Investing.com - Investing.com Australia
Cognition Therapeutics receives donation to extend DLB program - Investing.com
Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies - The Manila Times
Donor extends 2-year access to experimental DLB therapy for 32 people - Stock Titan
Press Release: Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia With Lewy Bodies - Moomoo
H.C. Wainwright Maintains Cognition Therapeutics(CGTX.US) With Buy Rating, Maintains Target Price $3 - Moomoo
Chardan Capital Maintains Cognition Therapeutics(CGTX.US) With Buy Rating, Cuts Target Price to $4 - Moomoo
COGNITION THERAPEUTICS INC 1Q 2026: Net income $(4.57M), EPS $(0.05) — 10-Q Summary - TradingView
Cognition Therapeutics (NASDAQ: CGTX) Q1 2026 loss narrows on lower R&D - Stock Titan
The fundamentals driving Cognition (CGTX) everyone should understand (Smart Money Outflows) 2026-05-08Volume Dry Up - The Legal Advocate
Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update - The Manila Times
Cognition Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Cognition Therapeutics (NASDAQ: CGTX) cuts Q1 2026 loss and projects cash runway into Q2 2027 - Stock Titan
Dementia-drug developer gets May 20 FDA meeting as 2027 data loom - Stock Titan
Cognition Therapeutics (NASDAQ: CGTX) CFO has 8,567 shares withheld for taxes - Stock Titan
Cognition Therapeutics Inc Stock (CGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):